Zhiguo Luo

987 total citations
60 papers, 571 citations indexed

About

Zhiguo Luo is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Zhiguo Luo has authored 60 papers receiving a total of 571 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 20 papers in Molecular Biology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Zhiguo Luo's work include Cutaneous Melanoma Detection and Management (11 papers), Cancer Diagnosis and Treatment (11 papers) and Melanoma and MAPK Pathways (8 papers). Zhiguo Luo is often cited by papers focused on Cutaneous Melanoma Detection and Management (11 papers), Cancer Diagnosis and Treatment (11 papers) and Melanoma and MAPK Pathways (8 papers). Zhiguo Luo collaborates with scholars based in China, United States and Ethiopia. Zhiguo Luo's co-authors include Conghua Xie, Fuxiang Zhou, Zhengkai Liao, Chunmeng Wang, Biqiang Zheng, Xianghua Wu, Yunfeng Zhou, Shiquan Liu, Wangjun Yan and Yu Xu and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Zhiguo Luo

57 papers receiving 557 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhiguo Luo China 16 276 240 172 93 53 60 571
Caterina Aversa Italy 12 285 1.0× 210 0.9× 222 1.3× 108 1.2× 36 0.7× 32 553
Xiaoyan Lin China 15 201 0.7× 214 0.9× 102 0.6× 101 1.1× 40 0.8× 36 518
Nicoletta Cordani Italy 14 223 0.8× 311 1.3× 282 1.6× 105 1.1× 46 0.9× 29 739
Eleonora Lai Italy 14 315 1.1× 205 0.9× 145 0.8× 154 1.7× 45 0.8× 46 572
Robert D. Van Horn United States 15 300 1.1× 350 1.5× 198 1.2× 63 0.7× 43 0.8× 20 702
Rosario Garrido United States 9 235 0.9× 335 1.4× 222 1.3× 71 0.8× 22 0.4× 11 651
Sharon Glaysher United Kingdom 16 286 1.0× 324 1.4× 143 0.8× 112 1.2× 57 1.1× 30 690
Dawei Yang China 9 274 1.0× 284 1.2× 150 0.9× 117 1.3× 76 1.4× 16 626
Oliver J. Stoetzer Germany 14 206 0.7× 256 1.1× 97 0.6× 113 1.2× 55 1.0× 29 625

Countries citing papers authored by Zhiguo Luo

Since Specialization
Citations

This map shows the geographic impact of Zhiguo Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhiguo Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhiguo Luo more than expected).

Fields of papers citing papers by Zhiguo Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhiguo Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhiguo Luo. The network helps show where Zhiguo Luo may publish in the future.

Co-authorship network of co-authors of Zhiguo Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Zhiguo Luo. A scholar is included among the top collaborators of Zhiguo Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhiguo Luo. Zhiguo Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhao, Ting, Biqiang Zheng, Wangjun Yan, et al.. (2025). Fruquintinib as first‐line or second‐line treatment in unresectable or metastatic soft‐tissue sarcoma: A prospective, single‐arm phase II study. Clinical and Translational Medicine. 15(4). e70308–e70308. 1 indexed citations
2.
Zhao, Ting, et al.. (2025). Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine. MedComm. 6(5). e70161–e70161. 1 indexed citations
3.
Wei, Xiaoting, Zhengyun Zou, Weizhen Zhang, et al.. (2024). Overall survival and efficacy subgroup analysis of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.. Journal of Clinical Oncology. 42(16_suppl). 9545–9545. 3 indexed citations
4.
5.
Xu, Yu, Xin Lin, Wei Sun, et al.. (2023). 1173P NRAS mutation as an independent prognostic factor for resectable Chinese acral melanoma. Annals of Oncology. 34. S697–S697.
6.
Jiang, Shiyu, Lin Kong, Yu Xu, et al.. (2023). Clinical features and prognosis of patients with metastatic ocular and orbital melanoma: A bi‐institutional study. Cancer Medicine. 12(15). 16163–16172. 5 indexed citations
7.
8.
9.
Si, Lu, Zhengyun Zou, Weizhen Zhang, et al.. (2023). Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.. Journal of Clinical Oncology. 41(16_suppl). 9510–9510. 5 indexed citations
10.
Sun, Wei, Yu Xu, Wangjun Yan, et al.. (2023). A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations. Cancer Medicine. 12(15). 15945–15954. 7 indexed citations
11.
Jiang, Shiyu, Xianghua Wu, Wangjun Yan, et al.. (2022). Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study. Clinical Cancer Research. 28(24). 5280–5289. 20 indexed citations
12.
Gu, Bingxin, Xin Liu, Shuoer Wang, et al.. (2022). Head-to-head evaluation of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma. European Journal of Nuclear Medicine and Molecular Imaging. 49(8). 2889–2901. 40 indexed citations
13.
Meng, Yanchun, Hao Tang, Zhiguo Luo, et al.. (2021). An integrated bioinformatics analysis to investigate the targets of miR-133a-1 in breast cancer. Translational Cancer Research. 10(3). 1238–1248. 2 indexed citations
14.
Zhang, Xiaowei, Feng Jin, Shiyu Jiang, et al.. (2021). Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data. Investigational New Drugs. 40(2). 453–460. 7 indexed citations
15.
Liu, Xin, Silong Hu, Yingjian Zhang, et al.. (2020). Sentinel node theory helps tracking of primary lesions of cancers of unknown primary. BMC Cancer. 20(1). 639–639. 6 indexed citations
16.
Xu, Yu, Wei Sun, Biqiang Zheng, et al.. (2019). DEPDC1B knockdown inhibits the development of malignant melanoma through suppressing cell proliferation and inducing cell apoptosis. Experimental Cell Research. 379(1). 48–54. 30 indexed citations
17.
Li, Ting, Lei Wang, Huijie Wang, et al.. (2016). A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib. Investigational New Drugs. 34(6). 701–706. 21 indexed citations
18.
19.
Zhou, Yunfeng, Wenjie Zhang, Xiao‐Lian Zhang, et al.. (2006). Apoptosis induced by short hairpin RNA-mediated STAT6 gene silencing in human colon cancer cells. Chinese Medical Journal. 119(10). 801–808. 13 indexed citations
20.
Cao, Zhen, Zhiguo Luo, Jing Dai, et al.. (2005). Relationship between telomere length and radiosensitivity in various human cancer cell lines. Chinese Journal of Cancer Research. 17(4). 241–245. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Caterina Aversa Breakdown of academic impact, for papers by Xiaoyan Lin Breakdown of academic impact, for papers by Nicoletta Cordani Breakdown of academic impact, for papers by Eleonora Lai Breakdown of academic impact, for papers by Robert D. Van Horn Breakdown of academic impact, for papers by Rosario Garrido Breakdown of academic impact, for papers by Sharon Glaysher Breakdown of academic impact, for papers by Dawei Yang Breakdown of academic impact, for papers by Oliver J. Stoetzer
Rankless by CCL
2026